Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
VANCOUVER, Washington, Jan. 03, 2017 -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Thursday, January 5, 2017, at 1:00 p.m. PT / 4:00 p.m. ET to provide an update on clinical trial and regulatory developments.
Management also announces that it will post a “Letter to Shareholders and Friends” from President and CEO Nader Pourhassan Ph.D. reviewing the Company’s progress and highlighting 2017 milestones to its corporate website at www.cytodyn.com on Thursday, January 5, 2017.
Conference Call and Webcast Instructions
CytoDyn’s management team will host a conference call and live audio webcast on January 5, 2017 at 1:00 p.m. PT / 4:00 p.m. ET.
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).
A live audio webcast may also be accessed via CytoDyn’s corporate web site at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link: http://cytodyn.equisolvewebcast.com/inv-call-1-5-17.
A replay of the conference call will be available until March 5, 2017. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13652328.
CONTACTS: Investors: LHA Jody Cain Office: 310-691-7100 E-mail: [email protected] Media: Nader Pourhassan, Ph.D. President & CEO Office: 360-980-8524 Email: [email protected]
